The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I

European Journal of Nuclear Medicine

Volumn 29, Issue 11, 2002, Pages 1421-1427

  Lees, William ^a,b   Mansberg, Robert ^a,b   Roberts, John ^a,b   Towson, Jocelyn ^a,b   Chua, Elizabeth ^a,b   Turtle, John ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

123I diagnostic imaging; 131I diagnostic imaging; Thyroid ablation; Thyroid cancer; Thyroid stunning

Indexed keywords

IODINE 123; IODINE 131; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG EFFICACY; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; RADIATION RESPONSE; RADIOISOTOPE THERAPY; THYROID CARCINOMA; THYROID GLAND; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING; CARCINOMA; COMPARATIVE STUDY; METASTASIS; METHODOLOGY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; RADIATION EXPOSURE; RETROSPECTIVE STUDY; SCINTISCANNING; THYROID TUMOR; WHOLE BODY COUNTING;

ADULT; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE-BODY COUNTING;

EID: 0036034967     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-002-0945-8     Document Type: Article

References (31)

1. Feld S. AACE clinical practice guidelines for the management of thyroid carcinoma. Endocr Practice 1997; 3:61-70.
2. Dulgeroff AJ, Hershman JM. Medical therapy for differentiated thyroid carcinoma. Endocr Rev 1994; 15:500-515.
3. Rawson RW, Rall JE, Peacock W. Limitations and indications in the treatment of cancer of the thyroid with radioactive iodine. J Clin Endocrinol 1951; 11:1128-1142.
4. Jeevanram RK, Shah DH, Sharma SM, et al. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 1986; 13:277-279.
5. Park H-M, Perkins OW, Edmonson JW, Schnute RB, Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994; 4:49-54.
6. Kim CK, Tse K, San Pedro E. Influence of various scanning doses on subsequent I-131 ablation of thyroid remnants [abstract]. J Nucl Med 1994; 35(Suppl):14P.
7. Huic D, Medvedec M, Dodig D, et al. Radioiodine uptake in thyroid cancer patients after diagnostic application of low-dose I-131. Nucl Med Commun 1996; 17:839-842.
8. Park H-M, Park Y-H, Zhou X-H. Detection of thyroid remnant/metastases without stunning: an ongoing dilemma. Thyroid 1997; 7:277-280.
9. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185 MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25:242-246.
10. Muratet JP, Daver M, Minier JF, Larra F. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid cancer. J Nucl Med 1998; 39:1546-1550.
11. Yeung HWD, Humm JL, Larson SM. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J Nucl Med 2000; 41:1082-1085.
12. Medvedec M, Grosev D, Loncaric S, Pavlinovic Z, Dodic G. Thyroid "stunning": Full-quantitative explanation based on radiation absorbed dose analysis [abstract]. Eur J Nucl Med 2000; 27:923.
13. Sabri O, Zimny M, Schreckenberger M, Meyer-Oelmann A, Reinartz P, Buell U. Does thyroid stunning exist? A model with benign thyroid disease. Eur J Nucl Med 2000; 27:1591-1597.
14. Hermanska J, Karny M, Zimak J, Jirsa L, Samal M, Vlcek P. Improved prediction of therapeutic absorbed doses of radioiodine in the treatment of thyroid carcinoma [abstract]. J Nucl Med 2001; 42:1084.
15. 131I diagnostic whole-body scanning [letter to editor]. J Nucl Med 2001; 42:986.
16. Berman M, Braverman LE, Burke J, et al. I-123, I-124, I-125, I-126, I-130, I-131 and I-132 as sodium iodide. MIRD Report No. 5. J Nucl Med 1975; 16:857-860.
17. Zanzonico PB. Age-dependent thyroid absorbed doses for radiobiologically significant radioisotopes of iodine. Health Phys 2000; 78:60-67.
18. Maxon HR, Thomas SR, Washburn LC, Hinnefeld JD. High-activity I-123 for the diagnostic evaluation of patients with thyroid cancer [abstract]. J Nucl Med 1993; 34(Suppl):42P.
19. Naddaf S, Young I, Rapun R, et al. Comparison between iodine-123 (I-123) and iodine-131 (I-131) sodium iodide total body scanning in thyroid cancer patients [abstract]. J Nucl Med 1996; 37(Suppl):251P.
20. Bautovich G, Towson JE, Eberl S, et al. Comparison of iodine-123 and iodine-131 as a scanning agent for the detection of metastatic thyroid cancer [abstract]. J Nucl Med 1997; 38(Suppl):150P.
21. Coakley AJ. Thyroid stunning. Eur J Nucl Med 1998; 25:203-204.
22. 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 1997; 18:505-512.
23. 131I. J Nucl Med 2000; 41:1198-1202.
24. 131I-scanned and non-scanned individuals. J Clin Endocrinol Metab 2001; 86:3507-3511.
25. Chengazi V, O'Mara RE. Reply to McMenemin et al. [reference 15]. J Nucl Med 2001; 42:986-987.
26. Medvedec M. Seeking a radiobiological explanation for thyroid stunning [letter]. Eur J Nucl Med 2001; 28:393-395.
27. Behr TM, Behe MP, Gratz S, Hufner M, Becker W. Factors influencing the dosimetry and the therapeutic outcome of I-131 therapy of differentiated thyroid cancer (DTC) [abstract]. J Nucl Med 2001; 42(Suppl):242.
28. Sinyuta B, Dzhuzha D. The influence of diagnostic radiation absorbed doses and time interval on the degree of thyroid stunning [abstract]. Eur J Nucl Med 2001; 28:1004.
29. Maxon HR, Enlargo E, Thomas SR, Hertzberg VS, Hinnefeld JD, Chen LS, Smith H, Cummings D, Aden MD. Radioiodine-131 therapy for well-differentiated thyroid cancer - A quantitative radiation dosimetric approach: Outcome and validation in 85 patients. J Nucl Med 1992; 32:1132-1136.
30. de Geus-Oei LF, Pauwels EKJ, Stokkel MPM. A comparison between low and high dose I-123 WBS in the follow-up of thyroid cancer [abstract]. Eur J Nucl Med 2000; 27(Suppl):931.
31. Jana S, Santiago JF, Young I, et al. Comparison of I-123 total body retention in disease-free cancer thyroid patients with and without thyrogen (rhTSH) injections [abstract]. Eur J Nucl Med 2000; 27(Suppl):931.